UNSPSC 51391612: Amrinone lactate

This classification denotes a calcium channel blocker with the molecular formula C10H9N3O.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I229274Y5B. European Medicines Agency schedules amrinone lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00512MIG. The term amrinone lactate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amrinone lactate under HS 29337900. SMILES: CC(C(=O)O)O.C1CNCCC1C2CC(C(=O)[NH]C2)N.

UNSPSC 51391612 Amrinone lactate is a Commodity code that in practice encompasses pharmaceutical products and related health-service supplies procured by state and local public health agencies. Recent solicitations under this code reflect demand for emergency medical countermeasures and prescription-fulfillment infrastructure rather than the amrinone compound alone. Issuing bodies include county health departments and state health and human services commissions pursuing both direct pharmaceutical procurement and program-level initiatives to manage prescription access and cost. The work ranges from routine supply purchases of naloxone and drug deactivation systems through competitive bidding to exploratory requests for information on direct-to-manufacturer prescription models that bypass traditional pharmacy benefit managers and wholesalers.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023; vendors must include shipping and delivery costs and hold workers' compensation, commercial general liability, and professional liability insurance. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on vendor experience with direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with a response deadline of April 3, 2026. Both solicitations reflect state and local interest in supply-chain alternatives and cost management in pharmaceutical procurement.